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With its incidence approaching mortality, and with over 300,000 new cases diagnosed 42 
worldwide in 2013, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth 43 
leading cause of cancer-related death and predicted to become the second by 2030 (1). 44 
More than 80% of PDAC patients are diagnosed late, with locally invasive and/or 45 
metastatic disease, resulting in negligible 5-year survival. Timely detection of PDAC 46 
is hampered by several factors: lack of specific clinical symptoms in the early stages, 47 
insufficient sensitivity of current imaging modalities and a lack of accurate, clinically 48 
utilisable biomarkers (2). Thus the quest for a simple, inexpensive and non-invasive 49 
test to detect PDAC early - whilst it is still amenable to surgical resection, continues. 50 
Detection of volatile organic compounds (VOCs) has come to the fore offering a 51 
novel approach for the detection of disease. It uses the odours that emanate from 52 
urine, breath and faeces and is akin to canine ‘sniffing’. These compounds are 53 
metabolic products and/or consequence of bacterial dysbiosis produced by the disease 54 
state (3, 4). We thus postulate that either altered cellular physiology or even alteration 55 
in the microbial milieu in patients with PDAC will alter the individual’s metabolome 56 
profile, such that the resultant VOC patterns that are emitted provide a characteristic 57 
signature that can be detected.  58 
 59 
Description of Technology 60 
For this study, we used a commercial gas analysis instrument (Owlstone Lonestar), 61 
based on ion mobility spectrometry (IMS) to analyse the VOCs emanating from 62 
patients’ urine samples. Patients’ information is summarised in Table 1. Midstream 63 
urine samples were collected and frozen at -80oC within 4 hours of collection for 64 
long-term storage. Prior to analysis, each sample was defrosted and heated to 40oC for 65 
10 minutes. The air above the sample (known as the headspace) was then passed into 66 
the Lonestar unit and the ion mobility measured. Each sample typically takes five 67 
minutes to analyse (60 seconds per sample to scan, with five repeats). Once all the 68 
samples were analysed, an existing data processing pipeline with four different 69 
classifiers was applied (Sparse Logistic Regression, Random Forest, Gaussian Process 70 
Classifier and Support Vector Machine). Age was not deemed to be a confounder 71 
based on our previous published work – supplementary material. PDAC urine 72 
samples were detected with a sensitivity (SN) of 0.91 (CI: 0.83-0.96) and specificity 73 
(SP) of 0.83 (CI: 0.73-0.90), with an area under the curve (AUC) of 0.92 (CI:0.88-74 
0.96), using a support vector machine algorithm – Figure 1c. The results were 75 
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validated by random data splitting into the training and test set: the machine algorithm 76 
system was trained using the first 100 samples and the results of the remaining 62 test 77 
samples were then predicted. This achieved similar results with AUC of 0.92 (CI: 78 
0.85-0.98), and SN and SP of 0.90 (CI: 0.74-0.98) and 0.81 (CI: 0.63-0.93), 79 
respectively.  We also compared early stage disease (I/II) with healthy individuals as 80 
well as early stage I/II with late stage disease (III/IV) using the same analysis 81 
pipeline. These revealed a sensitivity (SN) of 0.91 (CI: 0.78-0.97) and specificity (SP) 82 
of 0.78 (CI: 0.69-0.86), with an area under the curve (AUC) of 0.89 (CI: 0.83-0.94), 83 
and SN of 0.82 (CI: 0.67-0.92), SP of 0.89 (CI: 0.75-0.97) with AUC of 0.92 (CI: 84 
0.86-0.97), respectively, again using a support vector machine algorithm (Figures 1d 85 
and e). 86 
 87 
Video Description 88 
The Lonestar is a special type of Ion Mobility Spectrometer (IMS), based on a method 89 
called FAIMS, (Field Asymmetric Ion Mobility Spectroscopy). Developed and used 90 
extensively by the security services, it has recently been employed for the detection of 91 
VOCs in medicine. It has the advantage of being more reproducible and far more 92 
sensitive than electronic noses, whilst at the same time, it does not have the 93 
limitations of mass spectrometry, which requires specialised and expensive 94 
infrastructure. FAIMS is based on measuring the way that ionised molecules move in 95 
very high electric fields and due to the differences in this movement, the instrument is 96 
able to separate complex mixtures of chemicals that are found in biological samples. 97 
It practice, this is achieved by passing ionised molecules between two plates, where 98 
an asynchronous electric field is applied. This attracts, repels or has no effect of these 99 
ions. If an ion touches one of the plates it loses its charge, and thus only ions that exit 100 
the plates without touching either side are detected. To the asynchronous electric 101 
field, an additional fixed “compensation voltage” is added that counteracts the 102 
movement. Thus, by scanning through a range of different compensation voltages we 103 
are able to measure a large range of different mobilities. To improve separation, the 104 
magnitude of the electric field is raised through a series of values to create a 3D map 105 
of a urine sample. These are then analysed using our in house data processing 106 
pipeline, previously described when analysing urine samples with different disease 107 
groups (5). In brief, first a data compression wavelet and threshold is applied to 108 
reduce the size of the dataset (which in our case is more than 50,000 data points per 109 
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sample). Once completed, important features are sought within the compressed 110 
dataset, using a Wilcoxon rank-sum test, with a 10-fold cross-validation step. Such 111 
identified features can then be used with different classification algorithms to 112 
calculate clinically relevant values e.g. AUC, SN and SP of unknown samples. 113 
 114 
Take Home Message 115 
We have already showed that urine is a useful bio-fluid for detection of early stage, 116 
resectable pancreatic cancer (6,7).  In this proof of concept study, we demonstrate for 117 
the first time, utility of urine specimens to discriminate healthy individuals from 118 
PDAC patients also through detection of volatile organic compounds. Moreover, we 119 
have also shown the ability to separate healthy from early stage and early stage vs 120 
advanced disease. This was achieved using only 5 ml of urine sample and applying 121 
novel IMS technology, which offers a rapid, and more cost effective analysis 122 
compared with other gas analysis technologies. The obtained results demonstrate that 123 
urine analysis using IMS platform shows promise as an additional non-invasive 124 
approach for identification of patients with pancreatic cancer. 125 
 126 
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Table 1. Demographic information 
 
  Healthy controls (n = 81) Pancreatic Cancer (n=81) 
Age (mean ± SD) 51.4 ± 10.6 64.3 ± 23.7 
Sex (male) % 30.9 53.1 
Stage* 
  
      I n/a 4 
      IIA n/a 5 
      IIB n/a 35 
      III n/a 24 
      IV n/a 12 
 130 
*One case could not be assessed 131 
 132 
 133 
 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
  142 
 7 
References:  143 
1. Rahib L, et. al. Cancer Res. 2014;74(11):2913-21. 144 
2. Kaur S, et. al. Biomark Med. 2012;6(5):597-612. 145 
3. Arasaradnam RP, et. al.  Aliment Pharmacol Ther. 2014;39(8):780-9. 146 
4. Arasaradnam RP, et. al. Med Hypotheses. 2009;73(5):753-6. 147 
5. Covington JA, et. al. Analyst. 2015;140(20):6775-81. 148 
6. Debernardi S, et. al. Am J Cancer Res. 2015;5(11):3455-66. 149 
7. Radon TP, et. al. Clin Cancer Res. 2015;21(15):3512-21. 150 
 151 
  152 
 8 
Figure 1Legend 153 
Figure 1a) Representative image of FAIMS output showing the plume of ion dispersion from 154 
a single urine sample of a healthy control (A.U. is arbitrary units). The mobility of ions 155 
determines the shape of the plume (5). Figure 1b) shows similar plume of ion dispersion from 156 
a single urine sample of a patient with PDAC. Note the difference in the shape of the plume 157 
as reflected by the different ion mobility shown in red. Figure 1c) Receiver Operating 158 
Characteristic (ROC) curve showing performance of VOCs in differentiating healthy 159 
individuals from pancreatic cancer samples with AUC of 0.92 (CI: 0.88-0.96); SN=0.91 (CI: 160 
0.83-0.96); SP=0.83 (CI: 0.73-0.9); Figure 1d) Healthy individuals from early stage I/II (AUC 161 
=0.89; CI: 0.83-0.94); SN=0.91 (CI: 0.78-0.97); SP=0.78 (CI: 0.69-0.86). Figure 1e) shows 162 
early stage PDAC(I/II) could also be successfully separated from  advanced stage (III/IV) 163 
pancreatic cancer with AUC 0.92 (CI: 0.86-0.97); SN=0.82 (CI: 0.67-0.92); SP=0.89 (CI: 0.75-164 
0.97).  165 
